Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Biliary Tract Diseases

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 229 articles:
HTML format



Single Articles


    June 2020
  1. VAN IJZENDOORN SCD, Li Q, Qiu YL, Wang JS, et al
    Unequal effects of MYO5B mutations in liver and intestine determine the clinical presentation of low-GGT cholestasis.
    Hepatology. 2020 Jun 24. doi: 10.1002/hep.31430.
    PubMed     Abstract available


  2. VARTAK N, Guenther G, Joly F, Damle-Vartak A, et al
    Intravital dynamic and correlative imaging reveals diffusion-dominated canalicular and flow-augmented ductular bile flux.
    Hepatology. 2020 Jun 19. doi: 10.1002/hep.31422.
    PubMed     Abstract available


  3. ABUD A, Maddur H, Salem R
    Management of symptomatic portal cavernoma cholangiopathy via transplenic portal vein recanalization and TIPS.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31411.
    PubMed     Abstract available


  4. FABRIS L, Sato K, Alpini G, Strazzabosco M, et al
    The Tumor Microenvironment in Cholangiocarcinoma Progression.
    Hepatology. 2020 Jun 4. doi: 10.1002/hep.31410.
    PubMed     Abstract available


    May 2020
  5. DENEAU MR, Mack C, Perito ER, Ricciuto A, et al
    The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) index: a prognostic tool for children.
    Hepatology. 2020 May 28. doi: 10.1002/hep.31393.
    PubMed     Abstract available


  6. YAN C, Koda S, Wu J, Zhang BB, et al
    Roles of trained immunity in the pathogenesis of cholangiopathies: a novel therapeutic target.
    Hepatology. 2020 May 28. doi: 10.1002/hep.31395.
    PubMed     Abstract available


  7. GUNASEKARAN G, Bekki Y, Lourdusamy V, Schwartz M, et al
    Surgical Treatments of Hepatobiliary Cancers.
    Hepatology. 2020 May 21. doi: 10.1002/hep.31325.
    PubMed     Abstract available


  8. DEAN G, Hanauer S, Levitsky J
    The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications.
    Hepatology. 2020 May 11. doi: 10.1002/hep.31311.
    PubMed     Abstract available


  9. ZHANG Y, Wang H, Chen T, Wang H, et al
    C24 -Ceramide Drives Gallbladder Cancer Progression through Directly Targeting PIP4K2C to Facilitate mTOR Signaling Activation.
    Hepatology. 2020 May 6. doi: 10.1002/hep.31304.
    PubMed     Abstract available


  10. JAVITT NB
    Blocking Sodum-Taurocholate Cotransporting Polypeptide Stimulates Biliary Cholesterol and Phospholipid Secretion in Mice.
    Hepatology. 2020 May 4. doi: 10.1002/hep.31292.
    PubMed     Abstract available


    April 2020
  11. CHEN J, Vitetta L
    Letter to the Editors: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31269.
    PubMed     Abstract available


  12. O'ROURKE CJ, Munoz-Garrido P, Andersen JB
    Molecular targets in cholangiocarcinoma.
    Hepatology. 2020 Apr 18. doi: 10.1002/hep.31278.
    PubMed     Abstract available


  13. TRAUNER M, Chung C, Myers RP, Kowdley KV, et al
    Reply to HEP-20-0140 Letter to the Editors: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?
    Hepatology. 2020 Apr 12. doi: 10.1002/hep.31268.
    PubMed     Abstract available


  14. LARGHI A, Rimbas M, Ardito F, Rizzatti G, et al
    EUS-FNA for lymph nodes staging in cholangiocarcinoma: should it become standard of care?
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31266.
    PubMed     Abstract available


    March 2020
  15. RIMLAND CA, Tilson SG, Morell CM, Tomaz RA, et al
    Regional differences in human biliary tissues and corresponding in vitro derived organoids.
    Hepatology. 2020 Mar 29. doi: 10.1002/hep.31252.
    PubMed     Abstract available


  16. VATS R, Liu S, Zhu J, Mukhi D, et al
    Impaired bile secretion promotes hepatobiliary injury in Sickle Cell Disease.
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31239.
    PubMed     Abstract available


  17. ISAACS-TEN A, Echeandia M, Moreno-Gonzalez M, Brion A, et al
    Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability.
    Hepatology. 2020 Mar 13. doi: 10.1002/hep.31228.
    PubMed     Abstract available


  18. AZAD AI, Krishnan A, Troop L, Li Y, et al
    Targeted Apoptosis Of Ductular Reactive Cells Reduces Hepatic Fibrosis In A Mouse Model of Cholestasis.
    Hepatology. 2020 Mar 3. doi: 10.1002/hep.31211.
    PubMed     Abstract available


  19. LAVU S, Therneau TM, Harmsen WS, Mara KC, et al
    Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma.
    Hepatology. 2020 Mar 2. doi: 10.1002/hep.31146.
    PubMed     Abstract available


    February 2020
  20. WANG HH, de Bari O, Arnatt CK, Liu M, et al
    Activation of a novel estrogen receptor GPR30 enhances cholesterol cholelithogenesis in female mice.
    Hepatology. 2020 Feb 29. doi: 10.1002/hep.31212.
    PubMed     Abstract available


  21. ZHU Y, Kwong LN
    Insights into the origin of intrahepatic cholangiocarcinoma from mouse models.
    Hepatology. 2020 Feb 24. doi: 10.1002/hep.31200.
    PubMed     Abstract available


  22. CHATURANTABUT S, Shwartz A, Garnaas MK, LaBella K, et al
    Estrogen acts via estrogen receptor 2b to regulate hepatobiliary fate during vertebrate development.
    Hepatology. 2020 Feb 14. doi: 10.1002/hep.31184.
    PubMed     Abstract available


  23. NAULT JC, Villanueva A
    Biomarkers for hepatobiliary cancers.
    Hepatology. 2020 Feb 11. doi: 10.1002/hep.31175.
    PubMed     Abstract available


    January 2020
  24. MA W, Han C, Zhang J, Song K, et al
    The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.
    Hepatology. 2020 Jan 28. doi: 10.1002/hep.31141.
    PubMed     Abstract available


  25. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as potential mediators of pathogen-induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC).
    Hepatology. 2020 Jan 23. doi: 10.1002/hep.31140.
    PubMed     Abstract available


  26. GOEPPERT B, Folseraas T, Roessler S, Kloor M, et al
    Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities.
    Hepatology. 2020 Jan 10. doi: 10.1002/hep.31110.
    PubMed     Abstract available


  27. LIN A, Alpert L, Hart J, Chapman C, et al
    Lymphoepithelioma-like carcinomas - a rare variant of cholangiocarcinoma.
    Hepatology. 2020 Jan 6. doi: 10.1002/hep.31102.
    PubMed     Abstract available


  28. GOODE EC, Hirschfield GM, Rushbrook SM
    Reply.
    Hepatology. 2020;71:399-400.
    PubMed    


  29. WANG J, Geskus RB, Leeflang MMG, Ponsioen CY, et al
    Letter to the Editor: Fair Comparisons in the Arena of Risk Scores.
    Hepatology. 2020;71:398-399.
    PubMed    


    December 2019
  30. CAROTENUTO P, Hedayat S, Fassan M, Cardinale V, et al
    Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells.
    Hepatology. 2019 Dec 26. doi: 10.1002/hep.31094.
    PubMed     Abstract available


  31. JOB S, Rapoud D, Dos Santos A, Gonzalez P, et al
    Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma.
    Hepatology. 2019 Dec 25. doi: 10.1002/hep.31092.
    PubMed     Abstract available


  32. STUART L, Lambourne B, Turner P, Jones DE, et al
    HEP-19-1549 Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma.
    Hepatology. 2019 Dec 23. doi: 10.1002/hep.31089.
    PubMed     Abstract available


  33. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    PubMed     Abstract available


  34. LOZANO E, Asensio M, Perez-Silva L, Banales JM, et al
    MRP3-mediated chemoresistance in cholangiocarcinoma: Target for chemosensitization through restoring SOX17 expression.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31088.
    PubMed     Abstract available


  35. MALIKOWSKI T, Levy MJ, Gleeson FC, Storm AC, et al
    EUS-FNA is effective for lymph node staging in patients with cholangiocarcinoma.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31077.
    PubMed     Abstract available


  36. SHUNG DL, Assis DN
    Machine Learning in a Complex Disease: PREsTo Improves The Prognostication of Primary Sclerosing Cholangitis.
    Hepatology. 2019 Dec 18. doi: 10.1002/hep.31069.
    PubMed     Abstract available


  37. GUICCIARDI ME, Trussoni CE, LaRusso NF, Gores GJ, et al
    The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis.
    Hepatology. 2019 Dec 13. doi: 10.1002/hep.31067.
    PubMed     Abstract available


    November 2019
  38. OVEREEM AW, Li Q, Qiu YL, Carton-Garcia F, et al
    A molecular mechanism underlying genotype-specific intrahepatic cholestasis resulting from MYO5B mutations.
    Hepatology. 2019 Nov 21. doi: 10.1002/hep.31002.
    PubMed     Abstract available


  39. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    PubMed     Abstract available


    October 2019
  40. SHAHEEN R, Alsahli S, Ewida N, Alzahrani F, et al
    Biallelic mutations in TTC26 (IFT56) cause severe biliary ciliopathy in humans.
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30982.
    PubMed     Abstract available


    September 2019
  41. LIU Y, Chen K, Li F, Gu Z, et al
    Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice.
    Hepatology. 2019 Sep 30. doi: 10.1002/hep.30975.
    PubMed     Abstract available


  42. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    PubMed     Abstract available


  43. WAN ZH, Jiang TY, Shi YY, Pan YF, et al
    RPB5-mediating protein promotes cholangiocarcinoma tumorigenesis and drug resistance by competing with NRF2 for KEAP1 binding.
    Hepatology. 2019 Sep 21. doi: 10.1002/hep.30962.
    PubMed     Abstract available


  44. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
    Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
    Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
    PubMed     Abstract available


  45. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
    Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
    PubMed     Abstract available


  46. PRADHAN-SUNDD T, Kosar K, Saggi H, Zhang R, et al
    Wnt/beta-Catenin signaling plays a protective role in the Mdr2 KO murine model of cholestatic liver disease.
    Hepatology. 2019 Sep 6. doi: 10.1002/hep.30927.
    PubMed     Abstract available


    August 2019
  47. DU Y, Khandekar G, Llewellyn J, Polacheck W, et al
    A Bile Duct-on-a-Chip with Organ-Level Functions.
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30918.
    PubMed     Abstract available


  48. DIAO M, Li L, Cheng W
    Timing of choledochal cyst perforation.
    Hepatology. 2019 Aug 28. doi: 10.1002/hep.30902.
    PubMed     Abstract available


  49. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
    Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
    PubMed     Abstract available


  50. BEUERS U, Hohenester S
    Fatigue in Primary Biliary Cholangitis: no Place for Rituximab.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30906.
    PubMed     Abstract available


    July 2019
  51. KYRITSI K, Chen L, O'Brien A, Francis H, et al
    Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880.
    PubMed     Abstract available


  52. CARPINO G, Nevi L, Overi D, Cardinale V, et al
    Peribiliary gland niche participates in biliary tree regeneration in mouse and in human primary sclerosing cholangitis.
    Hepatology. 2019 Jul 22. doi: 10.1002/hep.30871.
    PubMed     Abstract available


  53. LEE MH, Gao YT, Huang YH, McGee EE, et al
    A Metallomic Approach to Assess Associations of Serum Metal Levels With Gallstones and Gallbladder Cancer.
    Hepatology. 2019 Jul 18. doi: 10.1002/hep.30861.
    PubMed     Abstract available


  54. JIA X, Lu S, Zeng Z, Liu Q, et al
    Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma.
    Hepatology. 2019 Jul 12. doi: 10.1002/hep.30852.
    PubMed     Abstract available


  55. WU SH, Hsu JS, Chen HL, Chien MM, et al
    Plectin Mutations in Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2019 Jul 3. doi: 10.1002/hep.30841.
    PubMed     Abstract available


    June 2019
  56. UEASILAMONGKOL P, Khamphaya T, Guerra MT, Rodrigues M, et al
    Type 3 inositol 1,4,5-trisphosphate receptor is increased and enhances malignant properties in cholangiocarcinoma.
    Hepatology. 2019 Jun 28. doi: 10.1002/hep.30839.
    PubMed     Abstract available


  57. O'ROURKE CJ, Matter MS, Nepal C, Caetano-Oliveira R, et al
    Identification of a pan-gamma-secretase inhibitor response signature for notch-driven cholangiocarcinoma.
    Hepatology. 2019 Jun 18. doi: 10.1002/hep.30816.
    PubMed     Abstract available


    May 2019
  58. HE J, Chen J, Wei X, Leng H, et al
    mTORC1 Signaling is Required for the Dedifferentiation from Biliary Cell to Bi-potential Progenitor Cell in Zebrafish Liver Regeneration.
    Hepatology. 2019 May 28. doi: 10.1002/hep.30790.
    PubMed     Abstract available


  59. ROSCAM ABBING RLP, Slijepcevic D, Donkers JM, Havinga R, et al
    Blocking sodium-taurocholate cotransporting polypeptide stimulates biliary cholesterol and phospholipid secretion.
    Hepatology. 2019 May 28. doi: 10.1002/hep.30792.
    PubMed     Abstract available


  60. TERZIROLI BERETTA-PICCOLI B, Thompson R, Foskett P, Cerny A, et al
    A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adulthood.
    Hepatology. 2019 May 24. doi: 10.1002/hep.30783.
    PubMed     Abstract available


  61. HOOGERLAND JA, Lei Y, Wolters JC, de Boer JF, et al
    Glucose-6-phosphate regulates hepatic bile acid synthesis in mice.
    Hepatology. 2019 May 18. doi: 10.1002/hep.30778.
    PubMed     Abstract available


  62. SIEW SM, Cunningham SC, Zhu E, Tay SS, et al
    Prevention of cholestatic liver disease and reduced tumorigenicity in a murine model of PFIC type 3 using hybrid AAV-piggyBac gene therapy.
    Hepatology. 2019 May 17. doi: 10.1002/hep.30773.
    PubMed     Abstract available


  63. SUTHERLAND N, Li Wai Suen CFD, Mills C, Lokan J, et al
    Fibrosing cholestatic hepatitis-like syndrome in an immunocompetent patient with an acute flare of chronic hepatitis B.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30763.
    PubMed     Abstract available


  64. SITTITHUMCHAREE G, Suppramote O, Vaeteewoottacharn K, Sirisuksakun C, et al
    Dependency of Cholangiocarcinoma on Cyclin D-Dependent Kinase Activity.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30704.
    PubMed     Abstract available


  65. JALAN-SAKRIKAR N, M De Assuncao T, Shi G, Aseem S, et al
    Proteasomal Degradation of Enhancer of Zeste Homologue 2 in Cholangiocytes Promotes Biliary Fibrosis.
    Hepatology. 2019 May 9. doi: 10.1002/hep.30706.
    PubMed     Abstract available


  66. XIAO Y, Liu R, Li X, Gurley EC, et al
    Long non-coding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30698.
    PubMed     Abstract available


    April 2019
  67. ALISON MR, Lin WR
    Periportal Sox9-positive hepatocytes: progenitors with a biliary leaning.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30687.
    PubMed     Abstract available


  68. XIE Y, Matsumoto H, Kennedy S, Newberry EP, et al
    Impaired chylomicron assembly modifies hepatic metabolism through bile acid dependent and transmissible microbial adaptations.
    Hepatology. 2019 Apr 20. doi: 10.1002/hep.30669.
    PubMed     Abstract available


  69. LIU R, Li X, Zhu W, Wang Y, et al
    Cholangiocyte-derived exosomal LncRNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis.
    Hepatology. 2019 Apr 15. doi: 10.1002/hep.30662.
    PubMed     Abstract available


  70. OVADIA C, Perdones-Montero A, Spagou K, Smith A, et al
    Enhanced microbial bile acid deconjugation and impaired ileal uptake in pregnancy repress intestinal regulation of bile acid synthesis.
    Hepatology. 2019 Apr 15. doi: 10.1002/hep.30661.
    PubMed     Abstract available


  71. LOZANO E, Macias RIR, Monte MJ, Asensio M, et al
    Causes of hOCT1-dependent cholangiocarcinoma resistance to sorafenib and sensitization by tumor-selective gene therapy.
    Hepatology. 2019 Apr 10. doi: 10.1002/hep.30656.
    PubMed     Abstract available


  72. KOELFAT KVK, Plummer MP, Schaap FG, Lenicek M, et al
    Gallbladder dyskinesia is associated with an impaired postprandial FGF19 response in critically ill patients.
    Hepatology. 2019 Apr 1. doi: 10.1002/hep.30629.
    PubMed     Abstract available


    March 2019
  73. RIZZOLO D, Buckley K, Kong B, Zhan L, et al
    Bile acid homeostasis in a Cyp7a1 & Cyp27a1 double knockout mouse model.
    Hepatology. 2019 Mar 12. doi: 10.1002/hep.30612.
    PubMed     Abstract available


  74. WANG C, Zheng X, Jiang P, Tang R, et al
    Genome Wide Association Studies of Specific Antinuclear Autoantibody Sub-phenotypes in Primary Biliary Cholangitis.
    Hepatology. 2019 Mar 10. doi: 10.1002/hep.30604.
    PubMed     Abstract available


    February 2019
  75. WEN W, Schwabe RF
    Soluble fibers improve metabolic syndrome but may cause liver disease and hepatocellular carcinoma.
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30565.
    PubMed     Abstract available


  76. HONDA A, Tanaka A, Kaneko T, Komori A, et al
    Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis.
    Hepatology. 2019 Feb 8. doi: 10.1002/hep.30552.
    PubMed     Abstract available


  77. ZAGORY JA, Fenlon M, Dietz W, Zhao M, et al
    PROMININ-1 promotes biliary fibrosis associated with biliary atresia.
    Hepatology. 2019 Feb 5. doi: 10.1002/hep.30550.
    PubMed     Abstract available


    January 2019
  78. PRATT DS
    Hepatology Elsewhere.
    Hepatology. 2019 Jan 23. doi: 10.1002/hep.30517.
    PubMed     Abstract available


  79. BERAUER JP, Mezina AI, Okou DT, Sabo A, et al
    Identification of PKD1L1 Gene Variants in Children with the Biliary Atresia Splenic Malformation Syndrome.
    Hepatology. 2019 Jan 21. doi: 10.1002/hep.30515.
    PubMed     Abstract available


  80. TRAUNER M, Gulamhusein A, Hameed B, Caldwell S, et al
    The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC.
    Hepatology. 2019 Jan 19. doi: 10.1002/hep.30509.
    PubMed     Abstract available


  81. GOEPPERT B, Toth R, Singer S, Albrecht T, et al
    Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30493.
    PubMed     Abstract available


  82. HEERKENS M, Dedden S, Scheepers H, Van Paassen P, et al
    Effect of plasmapheresis on cholestatic pruritus and autotaxin activity during pregnancy.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30496.
    PubMed     Abstract available


    December 2018
  83. XIE C, Duffy AG, Mabry-Hrones D, Wood B, et al
    Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer.
    Hepatology. 2018 Dec 22. doi: 10.1002/hep.30482.
    PubMed     Abstract available


  84. GOODE EC, Clark AB, Mells GM, Srivastava B, et al
    Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.
    Hepatology. 2018 Dec 19. doi: 10.1002/hep.30479.
    PubMed     Abstract available


  85. SOROKA CJ, Assis DN, Alrabadi LS, Roberts S, et al
    Bile-derived organoids from patients with primary sclerosing cholangitis recapitulate their inflammatory immune profile.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30470.
    PubMed     Abstract available


  86. FUNKE K, Rockey DC
    Cholestatic drug induced liver injury caused by mifepristone.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30465.
    PubMed     Abstract available


  87. MARONI L, Pinto C, Giordano DM, Saccomanno S, et al
    Ageing-related expression of Twinfilin-1 regulates cholangiocyte biological response to injury.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30466.
    PubMed     Abstract available


  88. RAND EB
    Cirrhotic Cardiomyopathy in children with BA: A new objective parameter to predict morbidity and mortality on the waitlist - and beyond!
    Hepatology. 2018 Dec 12. doi: 10.1002/hep.30419.
    PubMed     Abstract available


  89. HUANG L, Cai J, Guo H, Gu J, et al
    ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30404.
    PubMed     Abstract available


  90. KHAMBU B, Li T, Yan S, Yu C, et al
    Hepatic Autophagy Deficiency Compromises FXR Functionality and Causes Cholestatic Injury.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30407.
    PubMed     Abstract available


  91. WANG F, Wang J, Li Y, Yuan J, et al
    Gallstone disease and type 2 diabetes risk: A Mendelian randomization study.
    Hepatology. 2018 Dec 4. doi: 10.1002/hep.30403.
    PubMed     Abstract available


  92. DE JONG IEM, Matton APM, van Praagh JB, van Haaften WT, et al
    Peribiliary glands are key in regeneration of the human biliary epithelium after severe bile duct injury.
    Hepatology. 2018 Dec 2. doi: 10.1002/hep.30365.
    PubMed     Abstract available


    November 2018
  93. SANTAMARIA E, Rodriguez-Ortigosa CM, Uriarte I, Latasa MU, et al
    The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis.
    Hepatology. 2018 Nov 8. doi: 10.1002/hep.30348.
    PubMed     Abstract available


  94. TIRNITZ-PARKER JEE, Forbes SJ, Olynyk JK, Ramm GA, et al
    Cellular plasticity in liver regeneration - spotlight on cholangiocytes.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30340.
    PubMed     Abstract available


    October 2018
  95. CASTRO NARRO GE, Gamboa Dominguez A, Consuelo Sanchez A, Salazar Martinez A, et al
    Combined Hepatocellular-Cholangiocarcinoma in a Patient with Cirrhosis due to Cholesteryl Ester Storage Disease.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30331.
    PubMed     Abstract available


  96. BANALES JM, Inarrairaegui M, Arbelaiz A, Milkiewicz P, et al
    Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis.
    Hepatology. 2018 Oct 16. doi: 10.1002/hep.30319.
    PubMed     Abstract available


  97. GELLERT-KRISTENSEN H, Dalila N, Nielsen SF, Nordestgaard BG, et al
    Identification and replication of six new loci associated with gallstone disease.
    Hepatology. 2018 Oct 16. doi: 10.1002/hep.30313.
    PubMed     Abstract available


  98. ANEZ-BUSTILLOS L, Dao DT, Potemkin AK, Perez-Atayde AR, et al
    An Intravenous Fish Oil Based Lipid Emulsion successfully treats intractable pruritus and cholestasis in a patient with MVID.
    Hepatology. 2018 Oct 12. doi: 10.1002/hep.30311.
    PubMed     Abstract available


  99. MANSINI AP, Peixoto E, Jin S, Richard S, et al
    The chemosensory function of primary cilia regulates cholangiocyte migration, invasion and tumor growth.
    Hepatology. 2018 Oct 9. doi: 10.1002/hep.30308.
    PubMed     Abstract available


  100. PERUGORRIA MJ, Olaizola P, Banales JM
    Cholangiocyte-to-Hepatocyte Differentiation: a Context Dependent Process and an Opportunity for Regenerative Medicine.
    Hepatology. 2018 Oct 8. doi: 10.1002/hep.30305.
    PubMed     Abstract available


    September 2018
  101. SIRICA AE, Gores GJ, Groopman JD, Selaru FM, et al
    Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30289.
    PubMed     Abstract available


  102. CAI SY, Boyer JL
    Bile Infarcts - new insights into the pathogenesis of obstructive cholestasis.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30291.
    PubMed     Abstract available


  103. BLOKKER BA, Maijo M, Echeandia M, Galduroz M, et al
    Fine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver disease.
    Hepatology. 2018 Sep 19. doi: 10.1002/hep.30275.
    PubMed     Abstract available


  104. RUSSELL JO, Lu WY, Okabe H, Abrams M, et al
    Hepatocyte-specific beta-catenin deletion during severe liver injury provokes cholangiocytes to differentiate into hepatocytes.
    Hepatology. 2018 Sep 14. doi: 10.1002/hep.30270.
    PubMed     Abstract available


  105. KAMATH B, Mack CL
    From hepatocyte to cholangiocyte: the remarkable potential of transdifferentiation to treat cholestatic diseases.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30250.
    PubMed     Abstract available


    August 2018
  106. MUIR AJ, Levy C, Janssen HLA, Montano-Loza AJ, et al
    Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
    Hepatology. 2018 Aug 28. doi: 10.1002/hep.30237.
    PubMed     Abstract available


  107. YANG L, Zhou Y, Xu PP, Mourya R, et al
    Diagnostic Accuracy of Serum Matrix Metalloproteinase-7 for Biliary Atresia.
    Hepatology. 2018 Aug 28. doi: 10.1002/hep.30234.
    PubMed     Abstract available


  108. FRANCA A, Filho ACML, Guerra MT, Weerachayaphorn J, et al
    Effects of endotoxin on type 3 inositol 1,4,5-trisphosphate receptor in human cholangiocytes.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30228.
    PubMed     Abstract available


  109. CARPINO G, Cardinale V, Folseraas T, Overi D, et al
    Neoplastic transformation of peribiliary stem cell niche in cholangiocarcinoma arisen in primary sclerosing cholangitis.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30210.
    PubMed     Abstract available


  110. GHALLAB A, Hofmann U, Sezgin S, Vartak N, et al
    Bile micro-infarcts in cholestasis are initiated by rupture of the apical hepatocyte membrane and cause shunting of bile to sinusoidal blood.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30213.
    PubMed     Abstract available


  111. GORGIS NM, Kennedy C, Lam F, Thompson K, et al
    Clinical Consequences of Cardiomyopathy in Children with Biliary Atresia Requiring Liver Transplantation.
    Hepatology. 2018 Aug 3. doi: 10.1002/hep.30204.
    PubMed     Abstract available


  112. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30145.
    PubMed     Abstract available


  113. LAMBERTI D, Cristinziano G, Porru M, Leonetti C, et al
    HSP90 inhibition drives degradation of FGFR2 fusion proteins: implications for treatment of cholangiocarcinoma.
    Hepatology. 2018 Aug 1. doi: 10.1002/hep.30127.
    PubMed     Abstract available


    July 2018
  114. LOOMES KM, Spino C, Goodrich NP, Hangartner TN, et al
    Bone Density in Children with Chronic Liver Disease Correlates with Growth and Cholestasis.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30196.
    PubMed     Abstract available


  115. OGAWA K, Kamimura K, Terai S
    Anti-Programmed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis.
    Hepatology. 2018 Jul 23. doi: 10.1002/hep.30189.
    PubMed     Abstract available


  116. SAYINER M, Golabi P, Stepanova M, Younossi I, et al
    Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174.
    PubMed     Abstract available


    May 2018
  117. KHANNA A, Jopson L, Howel D, Bryant A, et al
    Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30099.
    PubMed     Abstract available


  118. LIAN M, Wang Q, Jiang X, Zhang J, et al
    The Immunobiology of RANKL and Myeloid Derived Suppressor Cell Activation in IgG4-related Sclerosing Cholangitis.
    Hepatology. 2018 May 18. doi: 10.1002/hep.30095.
    PubMed     Abstract available


  119. EATON JE, Vesterhus M, McCauley BM, Atkinson EJ, et al
    Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes in PSC: A Derivation & Validation Study Using Machine Learning.
    Hepatology. 2018 May 9. doi: 10.1002/hep.30085.
    PubMed     Abstract available


  120. TAYLOR SA, Green RM
    Bile acids, microbiota and metabolism.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30078.
    PubMed    


    April 2018
  121. RIZVI S, Gores GJ
    Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking through a Door Half-opened.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.30069.
    PubMed    


  122. TAYLOR AE, Carey AN, Kudira R, Lages CS, et al
    Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30061.
    PubMed     Abstract available


  123. BEDNAREK J, Traxinger B, Brigham D, Roach J, et al
    Cytokine-producing B cells promote immune-mediated bile duct injury in murine biliary atresia.
    Hepatology. 2018 Apr 20. doi: 10.1002/hep.30051.
    PubMed     Abstract available


  124. KONG B, Sun R, Huang M, Chow MD, et al
    A Novel Fibroblast Growth Factor 15 Dependent- and Bile Acid Independent-Promotion of Liver Regeneration in Mice.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30041.
    PubMed     Abstract available


    March 2018
  125. BEZERRA JA, Wells RG, Mack CL, Karpen SJ, et al
    BILIARY ATRESIA: Clinical and Research Challenges for the 21(st) Century.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29905.
    PubMed     Abstract available


  126. HOFMANN AF, Marschall HU
    Plasma Bile Acid Concentrations in Humans: Suggestions for Presentation in Tabular Form.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29909.
    PubMed    


  127. SOUFI N, Kohli R
    What's cold got to do with it? Cold induced thermogenesis and microbiome modification maybe regulated by bile acid physiology.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29899.
    PubMed    


  128. KENNEDY L, Hargrove L, Demieville J, Karstens A, et al
    Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2(-/-) mice and human cholangiocarcinoma tumorigenesis.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29898.
    PubMed     Abstract available


  129. PONSIOEN CY, Lindor KD, Mehta R, Dimick-Santos L, et al
    Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis.
    Hepatology. 2018 Mar 25. doi: 10.1002/hep.29882.
    PubMed     Abstract available


  130. SLIJEPCEVIC D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, et al
    NTCP inhibition has hepatoprotective effects in cholestasis in mice.
    Hepatology. 2018 Mar 24. doi: 10.1002/hep.29888.
    PubMed     Abstract available


    February 2018
  131. PATHAK P, Cen X, Nichols RG, Ferrell JM, et al
    Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
    Hepatology. 2018 Feb 27. doi: 10.1002/hep.29857.
    PubMed     Abstract available


  132. WU JF, Lee CS, Lin WH, Jeng YM, et al
    Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy.
    Hepatology. 2018 Feb 27. doi: 10.1002/hep.29856.
    PubMed     Abstract available


  133. LI X, Liu R, Huang Z, Gurley EC, et al
    Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and human.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29838.
    PubMed     Abstract available


  134. MANSINI AP, Lorenzo Pisarello MJ, Thelen KM, Cruz-Reyes M, et al
    MiR-433 and miR-22 dysregulations induce HDAC6 overexpression and ciliary loss in cholangiocarcinoma.
    Hepatology. 2018 Feb 6. doi: 10.1002/hep.29832.
    PubMed     Abstract available


  135. OLAIZOLA P, Perugorria MJ, Banales JM
    Towards Personalized Medicine for Intrahepatic Cholangiocarcinoma: Pharmacogenomic Stratification of Patients.
    Hepatology. 2018 Feb 2. doi: 10.1002/hep.29830.
    PubMed    


    January 2018
  136. LI Q, Dutta A, Kresge C, Bugde A, et al
    Bile acids stimulate cholangiocyte fluid secretion by activation of membraneTMEM16A Cl(-) channels.
    Hepatology. 2018 Jan 23. doi: 10.1002/hep.29804.
    PubMed     Abstract available


  137. BRUNT E, Aishima S, Clavien PA, Fowler K, et al
    cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.
    Hepatology. 2018 Jan 23. doi: 10.1002/hep.29789.
    PubMed     Abstract available


  138. GULAMHUSEIN AF, Lazaridis KN
    Primary Biliary Cholangitis, DNA and Beyond: The Relative Contribution of Genes.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29783.
    PubMed    


  139. ARNDTZ K, Hirschfield GM
    Quality of life and primary sclerosing cholangitis: the business of defining what counts.
    Hepatology. 2018 Jan 9. doi: 10.1002/hep.29775.
    PubMed    


    December 2017
  140. NEPAL C, O'Rourke CJ, Oliveira DV, Taranta A, et al
    Genomic Perturbations Reveal Distinct Regulatory Networks in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2017 Dec 26. doi: 10.1002/hep.29764.
    PubMed     Abstract available


  141. BAJAJ JS, Hylemon PB
    Gut-Liver Axis Alterations in Alcoholic Liver Disease: Are Bile Acids the Answer?
    Hepatology. 2017 Dec 22. doi: 10.1002/hep.29760.
    PubMed    


  142. SO J, Khaliq M, Evason K, Ninov N, et al
    Wnt/beta-catenin signaling controls intrahepatic biliary network formation in zebrafish by regulating Notch activity.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29752.
    PubMed     Abstract available


  143. ALI AH, Tabibian JH, Naser-Ghodsi N, Lennon RJ, et al
    Surveillance for Hepatobiliary Cancers in Patients with Primary Sclerosing Cholangitis.
    Hepatology. 2017 Dec 15. doi: 10.1002/hep.29730.
    PubMed     Abstract available


  144. LEVY C
    Evolving role of Obeticholic acid in primary biliary cholangitis.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29726.
    PubMed    


  145. MURILLO PEREZ F, Goet JC, Lammers WJ, Gulamhusein A, et al
    Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29717.
    PubMed     Abstract available


  146. LEVY D
    The role of mEH, NTCP and OATP in hepatic sodium-dependent bile acid transport.
    Hepatology. 2017 Dec 6. doi: 10.1002/hep.29712.
    PubMed    


  147. BOWLUS CL
    Scratching the surface of cholestatic itch treatments.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29698.
    PubMed    


    November 2017
  148. ONO SK, Bassit L, Van Vaisberg V, Avancini Ferreira Alves V, et al
    Acute acalculous cholecystitis during Zika virus infection in an immunocompromised patient.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29682.
    PubMed    


  149. ORNOLFSSON KT, Olafsson S, Bergmann OM, Gershwin ME, et al
    Using the Icelandic Genealogical Database to define the familial risk of primary biliary cholangitis.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29675.
    PubMed     Abstract available


  150. HARTMANN P, Hochrath K, Horvath A, Chen P, et al
    Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29676.
    PubMed     Abstract available


  151. YOUNOSSI ZM, Afendy A, Stepanova M, Racila A, et al
    Development and Validation of a Primary Sclerosing Cholangitis-Specific Patient-Reported Outcomes Instrument: The PSC PRO.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29664.
    PubMed     Abstract available


  152. SHARMA A, Gandhi CR
    "CHOP"ing intestinal stem cells on way to cholestatic liver injury.
    Hepatology. 2017 Nov 16. doi: 10.1002/hep.29656.
    PubMed    


  153. AFONSO MB, Rodrigues CMP
    microRevolution in understanding primary biliary cholangitis pathophysiology.
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29653.
    PubMed    


  154. SCHRAMM C, Eaton J, Ringe KI, Venkatesh S, et al
    Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group.
    Hepatology. 2017;66:1675-1688.
    PubMed     Abstract available


  155. ELLIS JL, Bove KE, Schuetz EG, Leino D, et al
    Zebrafish abcb11b mutant reveals novel strategies to restore bile excretion impaired by bile salt export pump deficiency.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29632.
    PubMed     Abstract available


  156. CARBONE M, Bonato G, Invernizzi P
    Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29625.
    PubMed    


    October 2017
  157. JANSEN PLM
    Hydrodynamics of bile flow Lessons from computational modelling.
    Hepatology. 2017 Oct 27. doi: 10.1002/hep.29618.
    PubMed    


  158. LIASKOU E, Hirschfield GM
    Genetic association studies and the risk factors for developing the 'immuno-bile-logic' disease PBC.
    Hepatology. 2017 Oct 24. doi: 10.1002/hep.29603.
    PubMed    


  159. JALAN-SAKRIKAR N, Huebert RC
    Ducts in a Dish: Bioengineered Biliary Scaffolds for Regenerative Medicine.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29614.
    PubMed    


  160. EHRLICH L, Glaser SS
    Novel beta-catenin/FXR Interaction Regulates Hepatic Bile Acid Metabolism During Cholestasis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29584.
    PubMed    


  161. KOWDLEY KV, Luketic V, Chapman R, Hirschfield GM, et al
    A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29569.
    PubMed     Abstract available


  162. FERANCHAK AP
    CFTR: Actin(g) as a master regulator of cholangiocyte function.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29583.
    PubMed    


  163. MASYUK AI, Masyuk TV, Lorenzo Pisarello MJ, Ding JF, et al
    Cholangiocyte Autophagy Contributes to Hepatic Cystogenesis in Polycystic Liver Disease and Represents a Potential Therapeutic Target.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29577.
    PubMed     Abstract available


  164. PRADHAN-SUNDD T, Zhou L, Vats R, Jiang A, et al
    Dual catenin loss in murine liver causes tight junctional deregulation and progressive intrahepatic cholestasis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29585.
    PubMed     Abstract available


    September 2017
  165. LIU R, Li X, Huang Z, Zhao D, et al
    CHOP-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29540.
    PubMed     Abstract available


  166. JAHN D, Geier A
    Bile acids in NASH: pathophysiological driving force or innocent bystanders?
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29543.
    PubMed    


  167. ERICE O, Munoz-Garrido P, Vaquero J, Perugorria MJ, et al
    MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.
    Hepatology. 2017 Sep 18. doi: 10.1002/hep.29533.
    PubMed     Abstract available


  168. BAE HR, Hodge DL, Yang GX, Leung PSC, et al
    The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29524.
    PubMed     Abstract available


  169. SULTAN M, Rao A, Elpeleg O, Vaz FM, et al
    Organic Solute Transporter-beta (SLC51B) Deficiency in Two Brothers with Congenital Diarrhea and Features of Cholestasis.
    Hepatology. 2017 Sep 12. doi: 10.1002/hep.29516.
    PubMed     Abstract available


  170. LUO Z, Jegga AG, Bezerra JA
    Gene-disease associations identify a connectome with shared molecular pathways in human cholangiopathies.
    Hepatology. 2017 Sep 2. doi: 10.1002/hep.29504.
    PubMed     Abstract available


  171. DELLAVANCE A, Ferraz MLG, Cancado ELR, Andrade LEC, et al
    Expansion and intensification of humoral autoimmune response in the transition from preclinical to full-blown primary biliary cholangitis.
    Hepatology. 2017;66:997.
    PubMed    


    August 2017
  172. VYAS D, Baptista PM, Brovold M, Moran E, et al
    Self-assembled liver organoids recapitulate hepato-biliary organogenesis in vitro.
    Hepatology. 2017 Aug 23. doi: 10.1002/hep.29483.
    PubMed     Abstract available


  173. DEMAREZ C, Gerard C, Cordi S, Poncy A, et al
    MiR-337-3p controls hepatobiliary gene expression and transcriptional dynamics during hepatic cell differentiation.
    Hepatology. 2017 Aug 17. doi: 10.1002/hep.29475.
    PubMed     Abstract available


  174. MONCSEK A, Al-Suraih MS, Trussoni CE, O'Hara SP, et al
    Targeting senescent cholangiocytes and activated fibroblasts with Bcl-xL inhibitors ameliorates fibrosis in Mdr2-/- mice.
    Hepatology. 2017 Aug 12. doi: 10.1002/hep.29464.
    PubMed     Abstract available


    July 2017
  175. GU J, Jeong S, Xia Q
    Intrahepatic cholangiocarcinoma arising from HBV Infection may be a highly selected population for liver transplantation.
    Hepatology. 2017 Jul 31. doi: 10.1002/hep.29413.
    PubMed    


  176. FIOROTTO R, Amenduni M, Mariotti V, Fabris L, et al
    Src kinase inhibition reduces inflammatory and cytoskeletal changes in DeltaF508 human cholangiocytes and improves CFTR correctors efficacy.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29400.
    PubMed     Abstract available


  177. THOMPSON MD, Moghe A, Cornuet P, Marino R, et al
    beta-catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29371.
    PubMed     Abstract available


  178. PURI P, Daita K, Joyce A, Mirshahi F, et al
    The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Hepatology. 2017 Jul 11. doi: 10.1002/hep.29359.
    PubMed     Abstract available


  179. PELLAT A, Vaquero J, Fouassier L
    Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
    Hepatology. 2017 Jul 3. doi: 10.1002/hep.29350.
    PubMed     Abstract available


    June 2017
  180. WANG DQ, Portincasa P, Tso P
    Transintestinal cholesterol excretion (TICE): A secondary, non-biliary pathway contributing to reverse cholesterol transport.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29341.
    PubMed    


  181. DAWSON PA
    Hepatic bile acid uptake in humans and mice: Multiple pathways and expanding potential role for gut-liver signaling.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29325.
    PubMed    


  182. ALVARO D
    The challenge of cholangiocarcinoma diagnosis: the turning point is in extracellular vesicles?
    Hepatology. 2017 Jun 12. doi: 10.1002/hep.29314.
    PubMed    


  183. CHOI TY, Khaliq M, Tsurusaki S, Ninov N, et al
    Bmp Signaling Governs Biliary-Driven Liver Regeneration in Zebrafish via Tbx2b and Id2a.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29309.
    PubMed     Abstract available


  184. LIBERAL R, Grant CR, Yuksel M, Graham J, et al
    Treg Conditioning Endows Activated Teff with Suppressor Function in Autoimmune Hepatitis/Autoimmune Sclerosing Cholangitis.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29307.
    PubMed     Abstract available


  185. QIAN Y, Yao W, Yang T, Yang Y, et al
    aPKC-iota/P-Sp1/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma.
    Hepatology. 2017 Jun 2. doi: 10.1002/hep.29296.
    PubMed     Abstract available


    May 2017
  186. ARBELAIZ A, Azkargorta M, Krawczyk M, Santos-Laso A, et al
    Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
    Hepatology. 2017 May 26. doi: 10.1002/hep.29291.
    PubMed     Abstract available


  187. CHIANG JYL
    Linking long non-coding RNA to control bile acid signaling and cholestatic liver fibrosis.
    Hepatology. 2017 May 24. doi: 10.1002/hep.29289.
    PubMed    


  188. TOMINAGA K, Kamimura K, Sakamaki A, Terai S, et al
    Intraductal Papillary Neoplasm of the Bile Duct: A Rare Liver Tumor Complicated by Malignancy.
    Hepatology. 2017 May 18. doi: 10.1002/hep.29266.
    PubMed    


  189. GUO GL
    Why are females more susceptible to cholestasis-induced liver injury - Could it be LncRNA H19?
    Hepatology. 2017 May 15. doi: 10.1002/hep.29255.
    PubMed    


  190. SLIJEPCEVIC D, Roscam Abbing RLP, Katafuchi T, Blank A, et al
    Hepatic uptake of conjugated bile acids is mediated by both NTCP and OATPs and modulated by intestinal sensing of plasma bile acid levels in mice.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29251.
    PubMed     Abstract available


  191. TANAKA T, Zhang W, Sun Y, Shuai Z, et al
    Autoreactive Monoclonal Antibodies from Patients with Primary Biliary Cholangitis Recognize Environmental Xenobiotics.
    Hepatology. 2017 May 3. doi: 10.1002/hep.29245.
    PubMed     Abstract available


    April 2017
  192. SONG Y, Liu C, Liu X, Trottier J, et al
    H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29209.
    PubMed     Abstract available


  193. MIELI-VERGANI G, Vergani D
    The riddle of juvenile sclerosing cholangitis.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29208.
    PubMed    


  194. DENEAU MR, El-Matary W, Valentino PL, Abdou R, et al
    The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29204.
    PubMed     Abstract available


  195. LEVY C
    Primary biliary cholangitis: Treatment options finally expand.
    Hepatology. 2017;65:1405-1407.
    PubMed    


    March 2017
  196. LI X, Liu R, Yang J, Sun L, et al
    The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2-/- mice.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29145.
    PubMed     Abstract available


  197. WAN Y, Meng F, Wu N, Zhou T, et al
    Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29138.
    PubMed     Abstract available


    February 2017
  198. LI H, Zhou ZQ, Yang ZR, Tong DN, et al
    MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
    Hepatology. 2017 Feb 14. doi: 10.1002/hep.29116.
    PubMed     Abstract available


  199. KRAWCZYK M, Rau M, Grunhage F, Schattenberg JM, et al
    The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29100.
    PubMed    


    January 2017
  200. WANG Y, Aoki H, Yang J, Peng K, et al
    The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29076.
    PubMed     Abstract available


  201. HARGROVE L, Kennedy L, Demieville J, Jones H, et al
    BDL-induced biliary hyperplasia, hepatic injury and fibrosis are reduced in mast cell deficient Kitw-sh mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29079.
    PubMed     Abstract available


  202. SHUAI Z, Wang J, Badamagunta M, Choi J, et al
    The Fingerprint of Antimitochondrial Antibodies and the Etiology of Primary Biliary Cholangitis.
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29059.
    PubMed     Abstract available


  203. BJORNSSON ES, Jonasson JG
    Idiosyncratic drug-induced liver injury associated with bile duct loss and vanishing bile duct syndrome: Rare but has severe consequences.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29040.
    PubMed    


  204. VIVEIROS A, Reiterer M, Schaefer B, Finkenstedt A, et al
    CCBE1 Mutation causing Sclerosing Cholangitis - Expanding the Spectrum of Lymphedema-Cholestasis Syndrome.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29037.
    PubMed    


  205. MARONI L, Hohenester SD, van de Graaf SF, Tolenaars D, et al
    Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice.
    Hepatology. 2017 Jan 5. doi: 10.1002/hep.29029.
    PubMed     Abstract available


    December 2016
  206. WANG KS, Tiao G, Bass LM, Hertel PM, et al
    Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29019.
    PubMed     Abstract available


  207. HAUSSINGER D, Keitel V
    Dual role of the bile acid receptor TGR5 for hepatic lipid metabolism in feast and famine.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29017.
    PubMed    


  208. QIU YL, Gong JY, Feng JY, Wang RX, et al
    Defects in MYO5B are associated with a spectrum of previously undiagnosed low gamma-glutamyltransferase cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29020.
    PubMed     Abstract available


  209. BRANDI G, De Lorenzo S, Palloni A, Biasco G, et al
    Aspirin for cholangiocarcinoma prevention: new targets to shift the dogma from ascertained risk to possible prevention (Reply to: Risk Factors for Cholangiocarcinoma: Aspirin-use and the Risk of Cholangiocarcinoma).
    Hepatology. 2016 Dec 23. doi: 10.1002/hep.28999.
    PubMed    


  210. TRAUNER M, Fuchs CD, Halilbasic E, Paumgartner G, et al
    New therapeutic concepts in bile acid transport and signaling for management of cholestasis.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28991.
    PubMed     Abstract available


  211. GUPTA R, Gupta J
    Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28994.
    PubMed    


  212. SAPISOCHIN G, Bruix J
    In response to: Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28993.
    PubMed    


  213. FAN W, Yang H, Liu T, Wang J, et al
    Prohibitin 1 Suppresses Liver Cancers Tumorigenesis in Mice and Human Hepatocellular and Cholangiocarcinoma cells.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28964.
    PubMed     Abstract available


  214. BONKOVSKY HL, Kleiner DE, Gu J, Odin JA, et al
    Clinical Presentations and Outcomes of Bile Duct Loss caused by Drugs and Herbal and Dietary Supplements.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28967.
    PubMed     Abstract available


  215. JANSEN PL, Ghallab A, Vartak N, Reif R, et al
    The ascending pathophysiology of cholestatic liver disease.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28965.
    PubMed     Abstract available


    November 2016
  216. DE VRIES EM, de Krijger M, Farkkila M, Arola J, et al
    Validation of the Prognostic Value of Histologic Scoring Systems in Primary Sclerosing Cholangitis; An International Cohort Study.
    Hepatology. 2016 Nov 23. doi: 10.1002/hep.28963.
    PubMed     Abstract available


  217. MOHANTY SK, Donnelly B, Lobeck I, Walther A, et al
    The SRL peptide of Rhesus Rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia.
    Hepatology. 2016 Nov 17. doi: 10.1002/hep.28947.
    PubMed     Abstract available


  218. SAMUR S, Klebanoff M, Banken R, Pratt DS, et al
    Long-term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis.
    Hepatology. 2016 Nov 7. doi: 10.1002/hep.28932.
    PubMed     Abstract available


  219. GRADILONE SA
    Extracellular vesicles as therapeutic carriers of microRNAs for cholangiocarcinoma.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28925.
    PubMed    


  220. ALTAII H, Al-Kindi SG, Oliveira GH, Yaqoob Z, et al
    Aspirin use and risk of cholangiocarcinoma: External validation with big data.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28920.
    PubMed    


  221. YAN S, Tang J, Zhang Y, Wang Y, et al
    Prostaglandin E2 promotes hepatic bile acid synthesis by an E prostanoid receptor 3-mediated hepatocyte nuclear receptor 4alpha/cholesterol 7alpha-hydroxylase pathway in mice.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28928.
    PubMed     Abstract available


    October 2016
  222. DESAI M, Mathur B, Eblimit Z, Vasquez H, et al
    Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28890.
    PubMed     Abstract available


  223. ZHANG L, Yang Z, Trottier J, Barbier O, et al
    LncRNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate Shp mRNA decay.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28882.
    PubMed     Abstract available


    September 2016
  224. DAHLQVIST G, Gaouar F, Carrat F, Meurisse S, et al
    Large-scale characterization study of patients with antimitochondrial antibodies but non-established primary biliary cholangitis.
    Hepatology. 2016 Sep 30. doi: 10.1002/hep.28859.
    PubMed     Abstract available


  225. LAGES CS, Simmons J, Maddox A, Jones K, et al
    The dendritic cell-Th17-macrophage axis controls cholangiocyte injury and disease progression in murine and human biliary atresia.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28851.
    PubMed     Abstract available


  226. KULKARNI SR, Soroka CJ, Hagey LR, Boyer JL, et al
    Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid fed mouse model of cholestasis.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28826.
    PubMed     Abstract available


  227. MCDANIEL K, Meng F, Wu N, Sato K, et al
    Forkhead box A2 regulated biliary heterogeneity and senescence during cholestatic liver injury.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28831.
    PubMed     Abstract available


  228. KAMINSKY P, Preiss J, Sasatomi E, Gerber DA, et al
    Biliary Adenofibroma: A Rare Hepatic Lesion with Malignant Features.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28818.
    PubMed    


  229. FIOROTTO R, Villani A, Kourtidis A, Scirpo R, et al
    CFTR controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28817.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: